Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9089)	3/10/1999 11:02:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

George, in regard to Murphy hotline tonight. His statement about DSMB telling Xoma to open discussion with the FDA, it hit me like a lightening bolt. You need to listen again to him about that 125 figure in my opinion and see if you come to the same conclusion as you posted previously. This whole situation is very strange to me. Now I know the FDA has some whimsical ideas about efficacy but SL and others keep trying to convince me their strong arm tactics for their pound of flesh are justified. You can't have it both ways. Either you have a solid statistical reproducible model or not. This is supposed to be science, not close enough for government work! Either they have some justified reasons for holding Xoma to strict mortality figure for efficacy or not. Now SL and others are backtracking and saying things like maybe close enough to mortality requirement and that trial might end this spring if requirement not reached. Gee whiz, what happened? Efficacy now has feet of clay? I wonder what genius on DSMB or FDA decides close enough for government work. Same types who voted for approval of Duract and Redux? FDA reform, when do we need it?